We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals

21 hedge funds and large institutions have $9.35M invested in Corbus Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital inflows, than outflows

Capital inflows: $511K | Capital outflows: $309K

0.42% more ownership

Funds ownership: 13.31% → 13.74% (+0.42%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

5% less funds holding

Funds holding: 22 → 21 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
21
Holders Change
-1
Holders Change %
-4.55%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
3
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CRBP Hedge Fund Activity: Q1 2016 in Review

21 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2016, worth a combined $9.35M — up 13% from $8.26M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CRBP and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Raymond James Financial Services Advisors, adding an estimated $197K. The largest seller was Spark Investment Management, exiting entirely with an estimated $214K sold.

  • 21 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2016, down from 22 in Q4 2015.
  • Funds reported $9.35M of Corbus Pharmaceuticals stock for Q1 2016, up 13% quarter-over-quarter.
  • 3 funds opened new Corbus Pharmaceuticals positions in Q1 2016 and 4 closed out, a net change of -1 holder.
  • The largest Corbus Pharmaceuticals buyer in Q1 2016 was Raymond James Financial Services Advisors, an estimated $197K added.
  • The largest Corbus Pharmaceuticals seller in Q1 2016 was Spark Investment Management, an estimated $214K sold.

Based on aggregated 13F filings for Q1 2016.